Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 TrialLancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019